ClinVar Miner

Submissions for variant NM_003221.4(TFAP2B):c.650del (p.Gly217fs) (rs1561964103)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Medical Genetics,American University of Beirut RCV000735439 SCV000853288 pathogenic Char syndrome 2017-11-14 criteria provided, single submitter clinical testing Char syndrome is caused by a genetic mutation in the transcription factor AP-2 Beta (TFAP2B) gene and follows an autosomal dominant mode of inheritance. Complete penetrance and variable expression have been reported. Various animal experimental studies showed that the TFAP2B gene product plays a critical role in the remodeling of the patent ductus arteriosus (PDA) as well as limb patterning. Most reported pathogenic variants in TFAP2B gene are missense mutations in the coding region, affecting the basic domain that is critical for DNA binding. Other reported mutations are intronic point mutations that alter splicing, or frameshift deletions. In this study we report a child with a novel heterozygous TFAP2B mutation c.650delG p.(Gly217Alafs*32), occurring de novo.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.